Compare KITT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | PHGE |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 6.9M |
| IPO Year | N/A | N/A |
| Metric | KITT | PHGE |
|---|---|---|
| Price | $1.21 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 12.2M | 62.5K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,840.00 | N/A |
| Revenue This Year | $2,936.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.38 | N/A |
| 52 Week Low | $0.71 | $4.10 |
| 52 Week High | $54.36 | $22.06 |
| Indicator | KITT | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 74.68 |
| Support Level | $0.71 | $4.10 |
| Resistance Level | $1.70 | $4.91 |
| Average True Range (ATR) | 0.19 | 0.30 |
| MACD | 0.08 | 0.39 |
| Stochastic Oscillator | 49.49 | 77.56 |
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).